Antibodies therapeutic

R. C. Das, K. J. Morrow, Antibody Therapeutics Production, Clinical trials, and Strategic issues 2002,... 

Harris, W. (1997). Antibody Therapeutics. CRC Press, Boca Raton, FL. 

Carter PJ. 2006. Potent antibody therapeutics by design. Nat Rev Immunol. 6 343-357. 

Research and Markets (2005d), Monoclonal antibody therapeutics current market dynamics future outlook. Available at http //www.researchandmarkets.com/ reportinfo.asp report id=75046 (accessed May 2005). 

An example of results from a tissue cross-reactivity study comparing binding of a monoclonal antibody therapeutic to human, cynomolgus monkey, and mouse tissues is shown in Table 9.2. A cell line that did not express the target was used as negative control tissue the same cell line transfected with the... 

The use of monoclonal antibodies as therapeutics has become commonplace. Antibodies or chi meric proteins against TNF-a are very effective in quelling certain inflammatory diseases. Trastuzumab (against HER2) is effective in reversing the growth of some breast tumors. As of 2005, there were 15 antibody therapeutics approved for use in the US. 

G. L. DeNardo, B. M. Bradt, G. R. Mirick, and S. J. DeNardo, Human antiglobulin response to foreign antibodies therapeutic benefit Cancer Immunol Immunother 52(5) 309-316 (2003). 

Das RC, Morrow KJ. Antibody market update. A supplement to D MD s antibody engineering and antibody therapeutics reports. Drug Market Dev 2002. 

Antibody therapeutics can potentially treat diseases that can be as diverse as autoimmune disorders to cancer and infectious diseases. Antibodies are currently rated as an important and growing class of biotherapeutics. Other than vaccines, monoclonal antibodies currently in development outnumber all other classes of therapeutics. Recombination technology plays a key role in the development and commercialization of therapeutic antibodies. In fact, eight of nine antibody products on the... 

For most antibody therapeutics, the stability in blood is not evaluated. However, the stability in blood should be evaluated for other proteins for example, if the protein has a heparin-binding domain, collection of plasma using heparin as the anticoagulant needs to be evaluated. This evaluation should be done on a case-by-case basis based on the properties of the therapeutic. 

To date, commercial antibody expression exclusively uses mammalian cell line expression. These mammalian cell lines have expression cassettes for the antibody heavy and light chain stably integrated into the host cell chromosome. The most commonly used cell lines are derived from Chinese hamster ovary (CHO) cells. About half the approved antibody therapeutics are made in CHO cell lines. The dihydrofolate reductase (dhfr) gene is used as a selectable marker owing to the development of CHO cell lines that are deficient for dhfr genes such as CHO DG44 and CHO... 

Jefferis, R., Glycosylation of recombinant antibody therapeutics. BiotechnoL Prog., 21, 11, 2005. Marder, et al.. Selective cloning of hybridoma cells for enhanced immunoglobulin production using flow cytometric cell sorting and automated laser nephelometry. Cytometry, 11, 498, 1990. 

To estimate the number of genes expressing products that could be accessible to antibody therapeutics, we assume that proteins are required to be located in the extracellular matrix. We also assume that the extracellular location is the union of secreted and transmembrane sets of proteins. Where the extracellular location is known, this is often included in Swiss-Prot and gene ontology (GO) [37] database annotation for the protein. Secreted proteins can be predicted by the presence of a signal peptide whilst transmembrane... 

---